We are delighted to share that Technophage’s Clinical Trial Director, Margarida Barreto, participated in the REVERSE 2 / TP-102_102 Investigator Meeting on 19th January 2025 in Hyderabad, India. The event was promoted and organized by our colleagues at VectorB2B – Drug Development, who were also represented at the meeting.
It was a true pleasure to meet the JSS Medical Research team in person, the CRO responsible for managing our trial in India, and to engage with the Principal Investigators from the various clinical trial sites of REVERSE 2.
Collaborating with such a dedicated and professional team is truly inspiring as we work together to drive innovation and advance the development of TP-102, an innovative bacteriophage cocktail for infected diabetic foot ulcers.